Manhattan Pharmaceuticals' President and CEO Named Panelist For Obesity Focus Session At BIO CEO & Investor Conference
Feb 10, 2006
NEW YORK, NY FEB. 10 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) announced today that Douglas Abel, president and chief executive officer, will be a panelist for the "Obesity: Advances in Obesity Drugs" Focus Session at the upcoming BIO CEO & Investor Conference in New York City. The Obesity Focus Session will be held on Tuesday, February 14, 2006 at 9:00 am Eastern Time in the Basildon Room of the Waldorf-Astoria, New York City.
The session will highlight new advances in obesity drugs, including Oleoyl-estrone (OE), Manhattan Pharma's orally administered small molecule in development for the treatment of obesity. The company expects to initiate a Phase IIa study for OE in the first half of 2006.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (www.manhattanpharma.com), a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.